ReceptivaDx: What the BCL6 Test Reveals About Endometriosis

Feb 15, 2026

In this sponsored episode of The Endometriosis Podcast, Dr. Nicholas Fogelson and Dr. Shanti Mohling are joined by Dr. Bruce Lessey—the researcher who identified BCL6 as a marker of endometrial inflammation—and Chris Jackson, CEO of Cicero Diagnostics, the company that brought his discovery to market as the ReceptivaDx test. Together, they explore how a gene first studied in lymphoma research became a tool for detecting progesterone resistance and inflammation linked to endometriosis. The conversation covers how the test works, who it’s most useful for, how accurate it is, what its limitations are, and where non-invasive diagnostics for endometriosis may be heading next.

Highlights:

• What BCL6 is and how it disrupts progesterone signaling and implantation
• How Dr. Lessey’s research became the ReceptivaDX clinical test
• When this test is most helpful in infertility and recurrent pregnancy loss
• What a positive result does—and doesn’t—mean
• Why earlier, less invasive diagnosis could change endometriosis care

For clinical consultations: contact Northwest Endometriosis and Pelvic Surgery in Portland, OR at [phone] or email us at [e-mail] 

Follow us on Instagram: @Nicholasfogelson and @drshantimohling

Download a transcript of this episode.